Lexicon Pharmaceutcl (LXRX) 15.03 $LXRX
Shares of LXRX Up 27.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jul 05, 1:05AM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 4 months, Lexicon Pharmaceuticals has returned 27.58% as of today's recent price of $14.41.
LXRX: 15.03 (+0.27)
Lexicon Pharmaceuticals Shares Up 20.8% Since SmarTrend's Buy Recommendation (LXRX)
Comtex SmarTrend(R) - Thu Jun 16, 1:40PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 4 months, Lexicon Pharmaceuticals has returned 20.76% as of today's recent price of $13.64.
LXRX: 15.03 (+0.27)
Shares of LXRX Up 30.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 09, 12:45AM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 3 months, Lexicon Pharmaceuticals has returned 30.41% as of today's recent price of $14.73.
LXRX: 15.03 (+0.27)
Lexicon To Present At The Jefferies 2016 Healthcare Conference
PR Newswire - Mon Jun 06, 3:01PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 8:30 a.m. Eastern Time in New York. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 15.03 (+0.27)
Premarket Research Report Covering the Biotech Industry
ACCESSWIRE - Mon Jun 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 6, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the biotech industry. Companies recently under review include Incyte, Chimerix, Lexicon Pharma, and Synthetic Biologics. Register with us now for your free membership and see our complete reports on these equities at:
SYN: 1.89 (+0.04), CMRX: 3.99 (-0.04), LXRX: 15.03 (+0.27), INCY: 85.70 (+2.17)
Lexicon Announces The Launch Of Aboutcarcinoid.com To Provide Carcinoid Syndrome Disease Education To Patients, Caregivers And Physicians
PR Newswire - Thu Jun 02, 3:15PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the launch of www.aboutcarcinoid.com to provide carcinoid syndrome disease education to patients, caregivers and physicians. Concurrent with the launching of the website, Lexicon is also working with seven leading national and regional patient advocacy groups to conduct the Carcinoid Syndrome Impact Survey, which is designed to improve understanding of the impact that carcinoid syndrome has on patient lives. Additional information on the survey can be found at www.aboutcarcinoid.com.
LXRX: 15.03 (+0.27)
Lexicon Pharmaceuticals Up 28.9% Since SmarTrend Uptrend Call (LXRX)
Comtex SmarTrend(R) - Wed Jun 01, 1:24PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 3 months, Lexicon Pharmaceuticals has returned 28.91% as of today's recent price of $14.56.
LXRX: 15.03 (+0.27)
Lexicon Announces FDA Priority Review Of New Drug Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
PR Newswire - Tue May 31, 7:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for telotristat etiprate, an oral drug for the treatment of carcinoid syndrome. The FDA has granted a Priority Review of the NDA filing and set a Prescription Drug User Fee Act ("PDUFA"
target action date of November 30, 2016.
LXRX: 15.03 (+0.27)
Lexicon Pharmaceuticals Up 14.5% Since SmarTrend Uptrend Call (LXRX)
Comtex SmarTrend(R) - Wed May 25, 1:18AM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 3 months, Lexicon Pharmaceuticals has returned 14.48% as of today's recent price of $12.93.
LXRX: 15.03 (+0.27)
Praveen Tyle, Ph.D. Joins Lexicon As Executive Vice President Of Research And Development
PR Newswire - Tue May 10, 7:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that Praveen Tyle, Ph.D. will join the company as its executive vice president of research and development, effective May 16, 2016, and will report to Lonnel Coats, Lexicon's president and chief executive officer. Dr. Tyle recently served as president, chief executive officer and board member of Osmotica Holdings and Osmotica Pharmaceutical.
LXRX: 15.03 (+0.27)
Lexicon reports 1Q loss
Automated Insights - Tue May 03, 6:20AM CDT
THE WOODLANDS, Texas (AP) _ Lexicon Pharmaceuticals Inc. (LXRX) on Tuesday reported a loss of $34.9 million in its first quarter.
LXRX: 15.03 (+0.27)
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 First Quarter Financial Results
PR Newswire - Tue May 03, 6:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2016 and provided an overview of key milestones for the company's lead drug candidates.
LXRX: 15.03 (+0.27)
Lexicon Pharmaceuticals Has Returned 24.8% Since SmarTrend Recommendation (LXRX)
Comtex SmarTrend(R) - Fri Apr 15, 1:38PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 1 month, Lexicon Pharmaceuticals has returned 24.83% as of today's recent price of $14.10.
LXRX: 15.03 (+0.27)
Lexicon To Present At The 15th Annual Needham Healthcare Conference
PR Newswire - Thu Apr 07, 3:01PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 11:20 a.m. Eastern Time in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 15.03 (+0.27)
Lexicon Submits New Drug Application To FDA For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
PR Newswire - Wed Mar 30, 4:02PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of telotristat etiprate, an oral drug for the treatment of carcinoid syndrome. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. Lexicon has requested a Priority Review by the FDA as part of the NDA filing.
LXRX: 15.03 (+0.27)
Lexicon To Present At The 36th Annual Cowen Healthcare Conference
PR Newswire - Thu Mar 03, 4:00PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 36th Annual Cowen Healthcare Conference on Wednesday, March 9, 2016 at 8:00 a.m. Eastern Time in Boston. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 15.03 (+0.27)
Lexicon Pharmaceuticals Shares Down 19.9% Since SmarTrend's Sell Call (LXRX)
Comtex SmarTrend(R) - Tue Feb 09, 10:07AM CST
SmarTrend identified a Downtrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on January 20th, 2016 at $9.85. In approximately 3 weeks, Lexicon Pharmaceuticals has returned 19.90% as of today's recent price of $7.89.
LXRX: 15.03 (+0.27)
Shares of LXRX Up 27.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jul 05, 1:05AM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 4 months, Lexicon Pharmaceuticals has returned 27.58% as of today's recent price of $14.41.
LXRX: 15.03 (+0.27)
Lexicon Pharmaceuticals Shares Up 20.8% Since SmarTrend's Buy Recommendation (LXRX)
Comtex SmarTrend(R) - Thu Jun 16, 1:40PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 4 months, Lexicon Pharmaceuticals has returned 20.76% as of today's recent price of $13.64.
LXRX: 15.03 (+0.27)
Shares of LXRX Up 30.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 09, 12:45AM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 3 months, Lexicon Pharmaceuticals has returned 30.41% as of today's recent price of $14.73.
LXRX: 15.03 (+0.27)
Lexicon To Present At The Jefferies 2016 Healthcare Conference
PR Newswire - Mon Jun 06, 3:01PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 8:30 a.m. Eastern Time in New York. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 15.03 (+0.27)
Premarket Research Report Covering the Biotech Industry
ACCESSWIRE - Mon Jun 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 6, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the biotech industry. Companies recently under review include Incyte, Chimerix, Lexicon Pharma, and Synthetic Biologics. Register with us now for your free membership and see our complete reports on these equities at:
SYN: 1.89 (+0.04), CMRX: 3.99 (-0.04), LXRX: 15.03 (+0.27), INCY: 85.70 (+2.17)
Lexicon Announces The Launch Of Aboutcarcinoid.com To Provide Carcinoid Syndrome Disease Education To Patients, Caregivers And Physicians
PR Newswire - Thu Jun 02, 3:15PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the launch of www.aboutcarcinoid.com to provide carcinoid syndrome disease education to patients, caregivers and physicians. Concurrent with the launching of the website, Lexicon is also working with seven leading national and regional patient advocacy groups to conduct the Carcinoid Syndrome Impact Survey, which is designed to improve understanding of the impact that carcinoid syndrome has on patient lives. Additional information on the survey can be found at www.aboutcarcinoid.com.
LXRX: 15.03 (+0.27)
Lexicon Pharmaceuticals Up 28.9% Since SmarTrend Uptrend Call (LXRX)
Comtex SmarTrend(R) - Wed Jun 01, 1:24PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 3 months, Lexicon Pharmaceuticals has returned 28.91% as of today's recent price of $14.56.
LXRX: 15.03 (+0.27)
Lexicon Announces FDA Priority Review Of New Drug Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
PR Newswire - Tue May 31, 7:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for telotristat etiprate, an oral drug for the treatment of carcinoid syndrome. The FDA has granted a Priority Review of the NDA filing and set a Prescription Drug User Fee Act ("PDUFA"
target action date of November 30, 2016. LXRX: 15.03 (+0.27)
Lexicon Pharmaceuticals Up 14.5% Since SmarTrend Uptrend Call (LXRX)
Comtex SmarTrend(R) - Wed May 25, 1:18AM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 3 months, Lexicon Pharmaceuticals has returned 14.48% as of today's recent price of $12.93.
LXRX: 15.03 (+0.27)
Praveen Tyle, Ph.D. Joins Lexicon As Executive Vice President Of Research And Development
PR Newswire - Tue May 10, 7:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that Praveen Tyle, Ph.D. will join the company as its executive vice president of research and development, effective May 16, 2016, and will report to Lonnel Coats, Lexicon's president and chief executive officer. Dr. Tyle recently served as president, chief executive officer and board member of Osmotica Holdings and Osmotica Pharmaceutical.
LXRX: 15.03 (+0.27)
Lexicon reports 1Q loss
Automated Insights - Tue May 03, 6:20AM CDT
THE WOODLANDS, Texas (AP) _ Lexicon Pharmaceuticals Inc. (LXRX) on Tuesday reported a loss of $34.9 million in its first quarter.
LXRX: 15.03 (+0.27)
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 First Quarter Financial Results
PR Newswire - Tue May 03, 6:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2016 and provided an overview of key milestones for the company's lead drug candidates.
LXRX: 15.03 (+0.27)
Lexicon Pharmaceuticals Has Returned 24.8% Since SmarTrend Recommendation (LXRX)
Comtex SmarTrend(R) - Fri Apr 15, 1:38PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 1 month, Lexicon Pharmaceuticals has returned 24.83% as of today's recent price of $14.10.
LXRX: 15.03 (+0.27)
Lexicon To Present At The 15th Annual Needham Healthcare Conference
PR Newswire - Thu Apr 07, 3:01PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 11:20 a.m. Eastern Time in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 15.03 (+0.27)
Lexicon Submits New Drug Application To FDA For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
PR Newswire - Wed Mar 30, 4:02PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of telotristat etiprate, an oral drug for the treatment of carcinoid syndrome. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. Lexicon has requested a Priority Review by the FDA as part of the NDA filing.
LXRX: 15.03 (+0.27)
Lexicon To Present At The 36th Annual Cowen Healthcare Conference
PR Newswire - Thu Mar 03, 4:00PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 36th Annual Cowen Healthcare Conference on Wednesday, March 9, 2016 at 8:00 a.m. Eastern Time in Boston. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 15.03 (+0.27)
Lexicon Pharmaceuticals Shares Down 19.9% Since SmarTrend's Sell Call (LXRX)
Comtex SmarTrend(R) - Tue Feb 09, 10:07AM CST
SmarTrend identified a Downtrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on January 20th, 2016 at $9.85. In approximately 3 weeks, Lexicon Pharmaceuticals has returned 19.90% as of today's recent price of $7.89.
LXRX: 15.03 (+0.27)
